Minnesota has enough Bicillin to treat 7% of the pregnant patients who need it — and your state may be worse — Labora Rounds

The signal

When the only effective treatment for a preventable cause of stillbirth exists at 7% of needed supply, you are not practicing medicine — you are practicing triage. Clinicians in Minnesota and similarly affected states must now make rationing decisions that were never part of their training: which pregnant patient gets the last vial?

Bicillin L-A (benzathine penicillin G 2.4 million units IM) is the only FDA-approved treatment for syphilis in pregnancy with proven efficacy in preventing vertical transmission. There is no equivalent alternative — ceftriaxone requires desensitization, has less evidence for congenital syphilis prevention, and requires ID consultation. A 7% supply-to-need ratio means rationing.

The pharmacist tells the doctor: “We have two vials left.” There are three pregnant women with positive syphilis tests this month. The doctor has to choose. Not which treatment to use — which patient gets treated at all. This isn’t a developing-country scenario. This is Minnesota, 2025.

What it means — by audience

The same signal, translated for the people who act on it.

For OB Providers

Call your pharmacy right now. How many vials of Bicillin L-A do you have? If the answer is fewer than 10, you are one positive RPR away from a clinical crisis. Build your rationing protocol before the situation forces one on you. Document every case where treatment was delayed by supply. Know your ceftriaxone alternative: 1g IV daily for 10–14 days, with desensitization for penicillin allergy and ID consultation.

For Midwives (CNM/CPM)

You cannot treat syphilis in a birth center. Your job is to screen universally and refer immediately — but “immediately” means knowing which clinic in your region actually has Bicillin this week, not assuming the hospital pharmacy does. Call ahead. Maintain a weekly-updated list of local treatment sites with confirmed supply, and walk positive referrals through personally.

For Birth Workers & Doulas

You’ll hear about this from your clients before the news does: “They said I have syphilis but they don’t have the medicine.” That’s real, and it’s terrifying. Validate the fear, then problem-solve: call the state health department STI hotline (many maintain a supply locator), connect your client to the nearest confirmed treatment site, and document the gap so someone can count it.

For Institutional Leaders

Quantify your exposure: how many syphilis-positive pregnant patients did your system see in the last 12 months? Multiply by your current Bicillin stock. If the ratio is below 50%, you are in crisis. Escalate to your CMO and state health officer, advocate for emergency production under the Defense Production Act, and publicly report every adverse neonatal outcome attributable to treatment delay.

For Everyone

Next steps

Contact your pharmacy today and confirm current Bicillin stock in vials on the shelf — not “we can order it.”
Establish a priority protocol: first-trimester positives and high-titer RPR results get treated first when supply is limited.
Develop a ceftriaxone desensitization pathway with your ID team for when Bicillin is unavailable — have it ready before you need it.
Report your supply gap to the FDA Drug Shortage Staff and your state epidemiologist by name.
Join or form a regional Bicillin advocacy coalition — individual hospitals cannot solve a national supply crisis alone.

Sources & provenance

Primary source: Labora Rounds · Research Intelligence, Health Infrastructure & Federal Agencies. — source-screenshot verification in progress.

Source: Labora Rounds · Research Intelligence, Health Infrastructure & Federal Agencies.
Status: Active shortage · Rationing the only proven treatment for syphilis in pregnancy.
Watch for: FDA Drug Shortage database updates for Bicillin L-A; Pfizer manufacturing announcements; state emergency declarations on penicillin supply; Senate HELP Committee hearings on drug shortages; your own pharmacy’s weekly inventory report.

← All research signals